On Nov 07, major Wall Street analysts update their ratings for $McKesson (MCK.US)$, with price targets ranging from $535 to $688.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $612.
BofA Securities analyst Allen Lutz maintains with a buy rating, and maintains the target price at $635.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $616 to $668.
Wells Fargo analyst Steve Baxter maintains with a hold rating, and maintains the target price at $535.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $652 to $651.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The stock's recent increase of 5% reflects a strong performance that counters the pessimistic view of long-term target risk.
The firm reported that McKesson's results showed robust performance across all segments, with particularly strong second-quarter performance in US Pharma. The expectation of an acceleration in segment EBIT for FY25, based on the midpoint guidance, is seen as encouraging.
McKesson has addressed several concerns and eliminated a number of significant obstacles. The company, along with its peers, has consistently reported strong updates. Additionally, large-cap healthcare appears to be comparatively under-invested and reasonably valued. There seems to be a solid rationale for the company to revert to its recently higher valuation multiples.
Here are the latest investment ratings and price targets for $McKesson (MCK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$麥克森 (MCK.US)$的評級，目標價介於535美元至688美元。
摩根士丹利分析師Erin Wright維持買入評級，維持目標價612美元。
美銀證券分析師Allen Lutz維持買入評級，維持目標價635美元。
巴克萊銀行分析師Stephanie Davis維持買入評級，並將目標價從616美元上調至668美元。
富國集團分析師Steve Baxter維持持有評級，維持目標價535美元。
TD Cowen分析師Charles Rhyee維持買入評級，並將目標價從652美元下調至651美元。
此外，綜合報道，$麥克森 (MCK.US)$近期主要分析師觀點如下：
股票最近上漲5%，反映了強勁表現，抵消了對長期目標風險的悲觀看法。
公司報告顯示，麥克森的業績在所有板塊表現強勁，特別是美國製藥板塊在第二季度表現突出。根據中點指引，預計FY25年各板塊EBIt加速增長，被視爲令人鼓舞的表現。
麥克森已解決了幾個問題，並消除了一些重大障礙。該公司及其同行們一直在持續發佈強勁的更新。此外，大型醫療保健板塊似乎投資相對不足，並且估值合理。該公司重新回歸到最近較高估值倍數似乎有充分的理由。
以下爲今日7位分析師對$麥克森 (MCK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
